Ethicon Endo-Surgery, REALIZE™ Adjustable Gastric Band For Morbid Obesity

September 28, 2007– Ethicon Endo-Surgery, Inc. announced the U.S. Food and Drug Administration (FDA) approved for marketing the REALIZE™ Adjustable Gastric Band, a surgical implant for weight reduction and improvement in obesity-related health conditions, such as type-2 diabetes, in individuals suffering from morbid obesity... Ethicon's Press Release -

METABOLEX , PHASE 2 TRIAL OF MBX-802, Study Will Assess Drug’s Benefit, Alone and with Lipitor®, in Overweight or Obese Patients

September 25, 2007 - Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug’s effect on dyslipidemia, insulin-resistance and obesity... Metabolex's Press release -

DOV Pharmaceutical, Significant Body Weight and BMI Reductions in Drug-Compliant Subjects in Phase Ib Clinical Study

Sept. 25 , 2007- DOV Pharmaceutical, Inc. announced additional Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity... DOV Pharmaceutical's Press Release -

Orexigen, positive results in two Phase I clinical trials of naltrexone, key component of the Company's lead product candidate for obesity, Contrave

Sep 25, 2007 - Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced positive results in two Phase I clinical trials of its proprietary sustained release (SR) formulation of naltrexone. Orexigen has developed this proprietary SR formulation of naltrexone with the objective of improving tolerability by modifying the pharmacokinetics of immediate release (IR) naltrexone. Naltrexone is a key component of the Company's lead product candidate for obesity, Contrave, which is currently being studied in Phase III clinical trials... Orexigen's Press Release -

Metabolex and Astellas, to identify potential drug candidates by examining genes associated with insulin resistance and obesity

September 19, 2007 / Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that Astellas Pharma Inc. has begun high-throughput screening against an additional target from Metabolex’s proprietary human gene database. Astellas is working to identify potential drug candidates by examining genes associated with insulin resistance and obesity... Metabolex's Press Release -

Arena Pharmaceuticals, Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review

Sept 11, 2007 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). The BLOOM trial is evaluating the efficacy and safety of lorcaserin hydrochloride for the treatment of obesity... Arena Pharmaceuticals' Press release -

Salugen , GenoTrim - a DNA Customized Nutritional Solution for Weight Management

Sept. 11, 2007 - Salugen, Inc., a personalized health and wellness company, announced the launch of GenoTrim, a DNA-based nutritional solution for weight management*. Attempts to achieve a healthy weight through both standard weight reduction strategies and numerous "gimmicks" have proven unsuccessful for the 58 million overweight individuals in the U.S. GenoTrim uniquely identifies specific genetic factors affecting hunger, metabolism and body composition that may contribute to the weight challenges of many of these individuals. Salugen's Press Release -
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Genaera, Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)

September 10th, 2007 -- Genaera Corporation (NASDAQ: GENR) announced the formation of its Trodusquemine Scientific Advisory Board (the “SAB”), consisting of leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance on the development of trodusquemine (MSI-1436), the Company’s novel small molecule drug candidate for the treatment of obesity and type 2 diabetes... Genaera's Press Release -

an obesity blog

The aim of the Blog "ObePosition" is to share information found in life sciences companies websites which could be interesting to follow new medical devices, pharmaceuticals, treatments, clinical trials for obesity.